Clinical Trial Goal
To find out:
- The highest dose of retifanimab, rituximab and tafasitamab that's safe to give before standard chemo
- If retifanimab, rituximab and tafasitamab before standard chemo is safe and works well to treat DLBCL that has had little to no treatment
You may be able to join this trial if you:
- Are 18 years or older
- Have one of the following and and have had little to no treatment:
- DLBCL
- Follicular lymphoma, grade 3b
- Other high-grade B-cell lymphoma
- Do not have lymphoma in your brain or spinal cord
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Cyclophosphamide, doxorubicin and vincristine are chemo drugs that block the growth of cancer cells.
Retifanlimab is a monoclonal antibody that targets PD-1 on certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
Tafasitamab is a monoclonal antibody that targets CD19 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
Retifanlimab is a monoclonal antibody that targets PD-1 on certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
Tafasitamab is a monoclonal antibody that targets CD19 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- Cyclophosphamide – Given as an intravenous (IV) infusion 1 time
- Doxorubicin – Given as an IV infusion 1 time
- Retifanlimab – Given as an IV infusion 1 time
- Rituximab – Given as a shot under your skin 1 time
- Tafasitamab– Given as an IV infusion 1 time each week
- Vincristine – Given as an IV infusion 1 time
You may continue treatment for up to 6 months. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat DLBCL is new and unproven.
Locations
Fred Hutch/University of Washington Cancer ConsortiumRECRUITING
Seattle, Washington
Stephen D. Smith, 206-606-6546, ssmith50@fredhutch.org
Sponsors
lead: University of Washington
